###### Strengths and limitations of this study

-   This study included a well-characterised cohort of adolescents and young adults at risk for diabetes.

-   All these individuals have undergone an oral glucose tolerance test (OGTT) to evaluate their alterations in insulin sensitivity and β-cell function.

-   This is the first study in a population of Chinese adolescents and young adults to assess the American Diabetes Association (ADA)'s haemoglobin A1c cut-points for predicting diabetes or pre-diabetes against the gold-standard OGTT.

-   However, there was a relatively small sample size of individuals with diabetes by ADA criteria in the population of youth.

-   While the study cohort was a large population-based sample, it may not be representative of the overall Chinese population as we chose to intensely study a subset at risk for the condition of interest (diabetes/pre-diabetes).

Introduction {#s1}
============

The incidence of obesity has increased dramatically in recent decades among Chinese children and adolescents. The Global Burden of Disease Study showed that the prevalence of overweight and obesity in children and adolescents in low-income and middle-income countries has increased from 8.4% in 1980 to 13.4% in 2013.[@R1] With the global surge in obesity, prevalence of diabetes has increased substantially. WHO data from 2014 estimated that 347 million people worldwide had diabetes.[@R2] A nationwide survey conducted by Yang *et al* in 2010 showed that the prevalence of diabetes and pre-diabetes among adults in China had reached 9.7% and 15.5%, respectively.[@R3] As both pre-diabetes and type 2 diabetes (T2DM) have emerged as consequences of childhood obesity,[@R4] the clustering of cardiovascular risk factors in this population[@R5] heightens concern that obese children and young adults are at risk for complications of diabetes, specifically cardiovascular disease (CVD). Thus, early identification of the population predisposed to developing diabetes is critically important if we are to target them for early intervention.

Screening for dysglycaemia (diabetes and pre-diabetes) has traditionally focused on OGTT to identify diabetes, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). However, due to time, expense and inconvenience, conducting an oral glucose tolerance test (OGTT) is often not feasible in patient care or population-based studies.[@R6] Fasting blood glucose (FBG) has been used as an inexpensive alternative to the OGTT, but FBG is also associated with challenges, like the requirement for an 8-hour fast. In a study of diabetes screening practices among paediatric clinicians, a strong preference for non-fasting tests was evident.[@R7]

Haemoglobin A1c (HbA1c) has become increasingly popular for diabetes screening among primary care providers due to its many practical advantages including convenience of sampling, suitability as an index of chronic dysglycaemia, low intraindividual variability and propitious assay standardisation.[@R8] In 2010, the American Diabetes Association (ADA)[@R9] suggested that HbA1c values of 5.7%--6.4% established a diagnosis of pre-diabetes while a value of ≥6.5% defined diabetes. These recommendations are based on data in adults showing the relationship between HbA1c and the subsequent development of diabetic microvascular complications. However, it remains controversial what HbA1c level should be applied to the definition of pre-diabetes in children and adolescents, with at least three proposed thresholds: 6.0%,[@R10] 5.7%[@R9]and 5.5%.[@R11] Furthermore, it is unclear at what ages these HbA1c thresholds should be applied, due to the paucity of longitudinal data in children (and even young adults) which associate these cut points with adverse cardiometabolic outcomes. Until these long-term outcome data become available, pre-diabetes and diabetes can best be defined by their ability to identify pathophysiological abnormalities associated with hyperglycaemia such as decreased β-cell function and insulin sensitivity.[@R12] Currently, studies in the Chinese paediatric population are lacking. Therefore, the aim of this study was to assess HbA1c as an instrument to establish the diagnosis of pre-diabetes and diabetes in a population of Chinese adolescents and young adults at increased risk of diabetes.

Materials and methods {#s2}
=====================

Subjects {#s2a}
--------

Subjects were recruited from the cohort of Beijing Children and Adolescents Metabolic Syndrome (BCAMS) study. The BCAMS is a longitudinal cohort study of cardiovascular risk factors since childhood. Details of the baseline study have been described previously.[@R13] Briefly, in 2004 a population-based survey was conducted in the Beijing area with a representative sample (n=19 593, 50% boys) of schoolchildren (aged 6--18 years). Approximately 4500 subjects were identified as being at elevated risk for dysglycaemia at baseline due to the presence of one of the following risk factors: overweight defined by body mass index (BMI), total cholesterol (TC) ≥5.2 mmol/L, triglyceride (TG) ≥1.7 mmol/L or FBG ≥5.6 mmol/L based on finger capillary blood tests. A follow-up study began in 2012 (8 years after baseline), with subjects recruited consecutively through various modalities (phone, text and email) for medical examination at Beijing Chaoyang Hospital. A total of 581 subjects who completed medical examination are included in this analysis. Those lost to follow-up were relatively younger and thinner at baseline than those who did follow-up; however, there were no significant difference in gender, pubertal status, blood pressure (BP), fasting TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and FBG levels (p\>0.05). The BCAMS study was registered at [www.clinicaltrials.gov](www.clinicaltrials.gov) (NCT03421444).

Patient and public involvement {#s2b}
------------------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design of this study. No patients were involved in the recruitment to and conduct of the study. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Clinical measurements {#s2c}
---------------------

Height, weight, waist circumference (WC) and per cent body fat (FAT%) were measured by trained field workers. Participants removed bulky clothing and shoes prior to measurements. Height was measured to the nearest 0.1 cm using a portable stadiometer. WC was measured midway between the lowest rib and the top of the iliac crest. Weight and FAT mass were measured to the nearest 0.1 kg using a Tanita Body Composition Analyzer (ModelTBF-300A). Measurements of right arm systolic and diastolic BP (SBP and DBP) were performed 3 times 10 min apart and the mean values of the latter two measurements were recorded. BMI was calculated as weight divided by height squared.

Laboratory measurements {#s2d}
-----------------------

Venous blood samples were collected after an overnight (≥12 hour) fast. An OGTT using 75 g glucose load was performed with plasma glucose levels in the fasting state (FBG), 0.5 hour and 2 hours (2hBG) measured using a hexokinase method. The concentrations of TG, TC and LDL-C were assayed using a standard enzymatic method. HDL-C was assessed with a phosphotungstic acid-Mg method. Serum C-reacting protein (CRP) was measured by immunoturbidimetric assay. Insulin concentrations were measured by monoclonal antibody-based sandwich enzyme-linked immunosorbent assays which was developed in the Key Laboratory of Endocrinology, Peking Union Medical College Hospital. The intra-assay and interassay coefficients of variation for insulin were \<5.4% and\<9.0%, respectively, with no cross-reactivity to proinsulin (\<0.05%). HbA1c was assayed using the TOSOH G7 automatic analysis system with high-pressure liquid chromatography. This assay is certified by the National Glycohemoglobin Standardization Program.

Insulin resistance was estimated by the following indices: (1) the homeostasis model assessment of insulin resistance (HOMA-IR) \[(fasting insulin mU/L)×(FBG mmol/L)/22.5\][@R15]; (2) Insulin Sensitive Index (Matsuda Index), \[ISI (Matsuda)=10 000/√((FBG×fasting plasma insulin)×(mean plasma glucose×mean plasma insulin))\].[@R16] Pancreatic β-cell function was assessed by: (1) homeostasis model assessment of β-cell function (HOMA-β) \[(20×fasting insulin)/(FPG-3.5)\][@R17]; (2) Insulinogenic Index (IGI=Δinsulin30/Δglucose30); (3) the ratio of the total area under the insulin curve to the total area under the glucose curve (total AUC insulin/glucose) and (4) the Oral Disposition Index (DI~O~=IGI×ISI) which is the product of insulin sensitivity and insulin secretion.[@R18]

Definitions {#s2e}
-----------

Dysglycaemia (IFG, IGT, pre-diabetes, diabetes) was defined according to current ADA guidelines.[@R9] Metabolic syndrome (MS) was diagnosed according to 2009 Joint Task Force harmonisation criteria, with subjects exhibiting at least three of the following five components[@R20]: (1) central obesity: WC ≥90th percentile for age and sex in 10--16 years, or ≥90 cm for male and ≥80 cm for female; (2) IFG, IGT or diabetes; (3) BP: ≥130/85 mm Hg; (4) HDL-C \<1.03 mmol/L in males, \<1.29 mmol/L in females and (5) TG ≥1.70 mmol/L. According to Chinese age-specific and sex-specific BMI cut-offs,[@R21] adolescents were classified as overweight if BMI was between the 85th and 95th percentile, and obese if BMI was above the 95th percentile. Subjects older than 18 years were classified overweight if BMI ≥24 kg/m^2^, or obese if BMI ≥28 kg/m^2^.

Data analysis {#s2f}
-------------

All statistical analyses were carried out using the Statistical Package for Social Sciences (SPSS V.19.0 for Windows). Continuous variables were tested for normality using a Kolmogorov-Smirnov test. Non-normal distribution values used in the analyses were log-transformed to improve normality. Results were expressed as mean±SD. Group comparisons across three HbA1c categories were made with analysis of variance with Bonferroni post hoc comparison test. Agreement between HbA1c, fasting glucose category and OGTT 2-hour glucose was also assessed. Κ coefficients were reported. Receiver operating characteristic (ROC) curve analysis was performed for HbA1c and FBG to discriminate pre-diabetes from normal glucose tolerance (NGT) and T2DM, from NGT and IGT using a logistic procedure. Area under the curve (AUC) was considered as an effective measure of inherent validity of a diagnostic test. The mean values of variables were studied by analysis of variance. Multivariate logistic regression models were used to estimate ORs for IR, MS and its components. Level of significance was accepted as p\<0.05.

Results {#s3}
=======

Subjects characteristics {#s3a}
------------------------

The mean age of the entire population was 20.2±2.9 years (female 46.8%). The prevalence rates of obesity, high BP, dyslipidaemia and MS were 32.6%, 20.2%, 29.5% and 14.5%, respectively. Of 581 subjects, 18 refused to conduct 2-hour-OGTT. Using the HbA1c criteria recommended by ADA, the prevalence of T2DM was 1.5% (9/581) and pre-diabetes was 13.4% (78/581), whereas employing OGTT criteria yielded somewhat different prevalence rates (IFG 4.8% (28/581), IGT 6.2% (35/563), IFG and/or IGT 10.1% (57/563) and T2DM 1.7% (10/581)).

Comparisons between HbA1c and fasting glucose {#s3b}
---------------------------------------------

The average HbA1c level was 5.4%±0.6%. HbA1c showed a strong positive correlation to FBG (r=0.734, p\<0.001), 2hBG (r=0.694, p\<0.001), but a modest negative correlation with ISI (r=−0.177, p\<0.001), IGI (r=−0.258, p\<0.001) and DI~O~ (r=−0.389, p\<0.001) ([table 1](#T1){ref-type="table"}). There were also modest correlations between HbA1c and various cardiometabolic parameters, such as TG (r=0.159, p\<0.001), TC (r=0.157, p\<0.001), LDL-C (r=0.176, p\<0.001), HDL-C (r=−0.103 p\<0.05), SBP (r=0.143, p=0.001) and hsCRP (r=0.111, p\<0.05). FBG showed similar correlation to these cardiometabolic parameters, except for hsCRP (p=0.125).

###### 

Correlation of HbA1c, glucose with cardiometabolic risk parameters

                       HbA1c         FBG          2hBG
  -------------------- ------------- ------------ -------------
  HbA1c (%)            1             0.734\*\*    0\. 694\*\*
  FBG (mmol/L)         0.734\*\*     1            0.718\*\*
  2hBG (mmol/L)        0\. 694\*\*   0.718\*\*    1
  TG (mmol/L)          0.159\*\*     0.182\*\*    0.196\*\*
  LDL-C (mmol/L)       0.176\*\*     0.108\*\*    0.152\*\*
  TC (mmol/L)          0.157\*\*     0.032        0.048
  HDL-C (mmol/L)       −0.103\*      −0.095\*     −0.102\*
  SBP (mm Hg)          0.143\*\*     0.151\*\*    0.219\*\*
  DBP (mm Hg)          0.209\*\*     0.63\*\*     0.238\*\*
  MS score             0.270\*\*     0.215\*\*    0.326\*\*
  Ln CRP (mg/L)†       0.112\*       0.069        0.126\*\*
  Ln ISI†              −0. 177\*\*   −0.226\*\*   −0.304\*\*
  Ln IGI†              −0.258\*\*    −0.213\*\*   −0.282\*\*
  Ln DI~O~†            −0.389\*\*    −0.386\*\*   −0.528\*\*
  Ln FINS (mU/L)†      0.169\*\*     0.182\*\*    0.198\*\*
  Ln 0.5hINS (mU/L)†   −0.096\*      −0.121\*\*   −0.083
  Ln 2hINS (mU/L)†     0.038         −0.025       0.357\*\*

MS score: numbers of MS components.

\*P\<0.05; \*\*P\<0.01.

†Log transformed before analysis.

0.5hINS, 0.5-hour insulin; 2hBG, 2-hour blood glucose; 2hINS, 2-hour insulin; CRP, C-reacting protein; DBP, diastolic blood pressure; DI~O~, Oral Disposition Index; FBG, fasting blood glucose; FINS, fasting insulin; HbA1c, haemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; IGI, Insulinogenic Index; ISI, Insulin Sensitivity Index; LDL-C: low-density lipoprotein cholesterol; Ln, Log transformed; MS, metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

The classification of subjects using HbA1c versus OGTT is shown in [table 2](#T2){ref-type="table"}. First, using OGTT data as a standard, the majority (7/10, 70.0%) of subjects with diabetes would have been diagnosed by HbA1c ≥6.5%. In contrast, only 25.7% (9/35) of subjects with IGT possessed elevated HbA1cs indicative of pre-diabetes, while the majority (68.6%) had normal HbA1cs. Second, the majority (87.6%) of the subjects with NGT would be identified with HbA1c \<5.7%, while 12.4% were classified with pre-diabetes or diabetes. On the other hand, of those considered to have diabetes by 2-hour OGTT (2hOGTT) criteria, 3 of 10 (30.0 %) were missed by HbA1c, while those identified as pre-diabetic on an OGTT (ie, IFG and/or IGT), 39 of 57 (68.4 %) were missed by HbA1c criteria.

###### 

The frequency of subjects with pre-diabetes and T2DM meeting the diagnostic criteria (HbA1c, FBG and 2hBG after 75 g-OGTT)

  OGTT    HbA1c\*      Total       FBG†       Total                                      
  ------- ------------ ----------- ---------- ------- ------------ ---------- ---------- ------
  NGT     454 (87.6)   64 (12.4)   0          518     497 (95.9)   21 (4.1)   0          518
  IGT     24 (68.6)    9 (25.7)    2 (5.7)    35      33 (94.3)    2 (5.7)    0          35
  T2DM    1 (10.0)     2 (20.0)    7 (70.0)   10      2 (20.0)     4 (40.0)   4 (40.0)   10
  Total   479 (85.1)   75 (13.3)   9 (1.6)    563‡    532 (94.5)   27 (4.8)   5 (0.7)    563‡

Numbers in brackets are percentages of horizontal total.

\*Kappa coefficient 0.21.

†Kappa coefficient 0.16.

‡18 of 581 subjects disagreed to undergo 2hOGTT.

75 g-OGTT, 75 g oral glucose tolerance test; 2hBG, 2-hour blood glucose; 2h-OGTT, 2-hour oral glucose tolerance test; FBG, fasting blood glucose; HbA1c, haemoglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes.

However, of those diagnosed with diabetes using OGTT, only 4 of 10 (40.0%) were identified by their FBG values, and among those with IGT, only 2 of 35 (5.7%) were identified with IFG. So, using FPG criteria to identify dysglycaemia would miss the majority of IGT and T2DM and using HbA1c was only moderately better (as demonstrated by the low k coefficients between either FBG (k=0.16) or HbA1c (k=0.21) and OGTT.

ROC curve analysis {#s3c}
------------------

[Figure 1A,B](#F1){ref-type="fig"} represent the diagnostic accuracy of the HbA1c and FBG, for IGT and diabetes identified by OGTT, respectively. The AUC for HbA1c was 0.624 (95% CI 0.582 to 0.664) and the AUC for FBG was 0.663 (0.576 to 0.749). The optimal HbA1c threshold for identifying IGT was 5.5%, with a sensitivity of 42.9% and specificity of 78.6%. To identify diabetes, the AUC for HbA1c was 0.970 (0.952 to 0.982), and for IFG the AUC was 0.789 (0.706 to 0.872). The optimal HbA1c threshold of 6.1%, identified diabetes with 90.0% sensitivity and 98.7% specificity.

![Comparison between the AUCs of the HbA1c and FBG for IGT (A) and T2DM (B) and the AUC of HbA1c for pre-diabetes (C). The green discontinuous line indicates the curve defining the area for the HbA1c, and the blue continuous curve defines the area for FBG. Pre-diabetes was defined either by an FBG ≥5.6 mmol/L (IFG) or 2hBG ≥7.8 mmol/L (IGT). The red arrows indicate the different thresholds (sensitivity, specificity) of HbA1c. 2hBG, 2-hour blood glucose; AUC, area under the curve; FBG, fasting blood glucose; HbA1c, haemoglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; ROC, receiver operating characteristic curve; SE, sensitivity; SP, specificity; T2DM, type 2 diabetes.](bmjopen-2017-020665f01){#F1}

In light of the inconsistency between IFG and IGT when identifying dysglycaemia, we defined pre-diabetes as either IFG or IGT, and evaluated HbA1c test performance with ROC. As shown in [figure 1C](#F1){ref-type="fig"} and [table 3](#T3){ref-type="table"}, the AUC of HbA1c for pre-diabetes was 0.680 (95% CI 0.640 to 0.719), and the optimal threshold of HbA1c was still 5.5%, with a sensitivity of 61.4% and specificity of 68.5%. Moreover, as shown in [figure 1 and](#F1){ref-type="fig"} [table 3](#T3){ref-type="table"}, compared with the ADA criteria for HbA1c (5.7%), lowering the HbA1c threshold to 5.5% doubles the sensitivity of this test, while only moderately affecting the specificity.

###### 

Test performance characteristics of specific HbA1c thresholds for detecting pre-diabetes and diabetes according to OGTT

  HbA1c threshold   Pre-diabetes (IFG+IGT)   T2DM                            
  ----------------- ------------------------ ------- ------- ------- ------- -------
  2.7               1.000                    1.000   1.000   1.000   1.000   1.000
  3.8               1.000                    0.998   1.002   1.000   0.998   1.002
  4.0               1.000                    0.996   1.004   1.000   0.996   1.004
  4.1               1.000                    0.994   1.006   1.000   0.995   1.005
  4.3               1.000                    0.992   1.008   1.000   0.993   1.007
  4.5               1.000                    0.990   1.010   1.000   0.991   1.009
  4.7               0.982                    0.986   0.997   1.000   0.986   1.014
  4.8               0.982                    0.972   1.011   1.000   0.973   1.027
  4.9               0.982                    0.950   1.033   1.000   0.953   1.047
  5.0               0.965                    0.911   1.054   1.000   0.917   1.083
  5.1               0.895                    0.853   1.042   1.000   0.857   1.143
  5.2               0.877                    0.764   1.113   1.000   0.776   1.224
  5.3               0.825                    0.615   1.210   1.000   0.635   1.365
  5.4               0.702                    0.452   1.250   1.000   0.476   1.524
  5.5               0.614                    0.315   1.300   1.000   0.344   1.656
  5.6               0.491                    0.200   1.292   0.900   0.228   1.672
  5.7               0.316                    0.115   1.201   0.900   0.136   1.764
  5.8               0.175                    0.058   1.117   0.900   0.071   1.829
  5.9               0.123                    0.026   1.097   0.900   0.036   1.864
  6.0               0.070                    0.014   1.056   0.900   0.020   1.880
  6.1               0.070                    0.006   1.064   0.900   0.013   1.887
  6.2               0.070                    0.004   1.066   0.800   0.011   1.789
  6.3               0.053                    0.004   1.049   0.800   0.009   1.791
  6.4               0.035                    0.002   1.033   0.800   0.005   1.795
  6.5               0.035                    0.000   1.035   0.700   0.004   1.696
  6.8                                                        0.700   0.000   1.700
  7.1                                                        0.600   0.000   1.600
  7.4                                                        0.500   0.000   1.500
  8.4                                                        0.400   0.000   1.400
  9.5                                                        0.300   0.000   1.300
  10.4                                                       0.200   0.000   1.200
  12.5                                                       0.100   0.000   1.100
  14.8                                                       0.000   0.000   1.000

HbA1c, haemoglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes.

Comparisons of metabolic characteristics according to different HbA1c criteria {#s3d}
------------------------------------------------------------------------------

To compare the segregation of metabolic characteristics among groups identified by our proposed HbA1c thresholds versus the ADA criteria, we stratified the population according to HbA1c categories ([table 4](#T4){ref-type="table"}). Age distribution, BMI, WC, DBP, FBG and 2hBG (all p\<0.05) were all different among the three categories defined by either ADA or our proposed thresholds, while HDL-C was not. Not surprisingly, there were more subjects (32.9% vs 13.4%) classified as pre-diabetic based on HbA1c 5.5%--6.1% than by ADA criteria of 5.7%--6.4%. Similarly, a greater number of subjects 16 (2.8%) vs 9 (1.5%) would be considered to have T2DM by our criteria.

###### 

Clinical features of the study population according to haemoglobin A1c categories

                        ADA criteria   P values         Our proposed criteria   P values                                                         
  --------------------- -------------- ---------------- ----------------------- ---------- --------------- ---------------- -------------------- ---------
  N                     494            78               9                                  374             191              16                   
  Age (years)           20.30 (0.13)   19.28 (0.33)\*   22.11 (0.86)†           0.001      20.38 (0.14)    19.67 (0.23)\*   21.33 (0.90)         0.010
  Sex (M/F)             253/241        49/29            6/3                     0.115      189/185         108/83           11/5                 0.176
  BMI (kg/m^2^)         25.41 (0.24)   27.53 (0.83)\*   28.73 (2.82)            \<0.001    25.03 (0.26)    26.90 (6.46)\*   28.65 (2.11)†        \<0.001
  WC (cm)               84.4 (0.6)     89.7 (2.1)\*     97.7 (7.8)†             \<0.001    83.4 (0.7)      88.5 (1.12)\*    94.0 (5.6)†          \<0.001
  SBP (mm Hg)‡          114.7 (0.5)    114.5 (1.2)      127.5 (3.6)†§           0.002      114.6 (0.6)     115.1 (0.8)      119.2 (2.7)          0.251
  DBP (mm Hg)‡          72.9 (0.39)    75.2 (1.0)       81.7 (2.9)†             0.003      72.3 (0.5)      74.9 (0.6)¶      78.3 (2.2)\*\*       \<0.001
  FBG (mmol/L)‡         4.85 (0.03)    4.99 (0.08)      9.24 (0.23)†§           \<0.001    4.82 (0.04)     4.94 (0.06)      7.61 (0.19)\*\*††    \<0.001
  2hBG (mmol/l)‡        5.87 (0.07)    6.46 (0.18)\*    16.43 (0.51)†§          \<0.001    5.80 (0.09)     6.15 (0.12)      12.89 (0.41)\*\*††   \<0.001
  IFG, n (%)            16 (3.2)       8 (10.3)\*       4 (44.4)†§              \<0.001    6 (1.6)         15 (7.9)¶        7 (43.8)\*\*††       \<0.001
  IGT, n (%)            24 (5.0)       9 (12.0)\*       2 (22.2)†§              \<0.001    16 (4.4)        17 (9.2)¶        2 (12.5)\*\*††       \<0.001
  Pre-diabetes, n (%)   39 (8.1)       16 (21.3)\*      2 (22.2)†               \<0.001    22 (6.1)        30 (16.3)¶       4 (25.0)\*\*         \<0.001
  T2DM, n (%)           1 (0.2)        2 (2.6)          7 (77.8%)†§             \<0.001    0 (0%)          1 (0.5%)         9 (56.3%)\*\*††      \<0.001
  Ln FINS (mIU/L)‡‡     1.92 (0.03)    1.97 (0.07)      2.64 (0.21)†§           0.003      1.92 (0.03)     1.95 (0.04)      2.13 (0.16)          0.421
  Ln 2h-INS (mU/L)‡‡    3.58 (0.03)    3.76 (0.09)      3.73 (0.30)             0.164      3.60 (0.04)     3.60 (0.06)      3.76 (0.21)          0.778
  Ln HOMA-IR‡‡          0.38 (0.02)    0.46 (0.07)      1.58 (0.22)†§           \<0.001    0.38 (0.03)     0.42 (0.05)      0.91 (0.17)\*\*††    0.007
  Ln HOMA-β‡‡           4.66 (0.03)    4.63 (0.07)      4.30 (0.22)             0.280      4.68 (0.03)     4.64 (0.04)      4.09 (0.16)\*\*††    0.002
  Ln ISI‡‡              1.81 (0.02)    1.72 (0.06)      0.95 (0.21)†§           \<0.001    1.81 (0.03)     1.79 (0.04)      1.45 (0.15)\*\*††    0.068
  Ln IGI‡‡              0.25 (0.04)    0.12 (0.09)      −1.20 (0.3)†§           \<0.001    0.30 (0.04)     0.14 (0.06)¶     −1.14 (0.22)\*\*††   \<0.001
  Ln DI~O~‡‡            2.06 (0.03)    1.84 (0.09)\*    −0.21 (0.32)†§          \<0.001    2.11 (0.04)     1.92 (0.06)¶     0.38 (0.21)\*\*††    \<0.001
  LDL-C (mmol/L)‡       2.50 (0.03)    2.62 (0.08)      3.47 (0.24)†§           \<0.001    2.49 (0.04)     2.58 (0.05)      2.95 (0.18)\*\*      0.022
  HDL-C (mmol/L)‡       1.43 (0.01)    1.45 (0.03)      1.35 (0.10)             0.609      1.44 (0.02)     1.42 (0.02)      1.50 (0.07)          0.576
  TC (mmol/L)‡          4.30 (0.04)    4.56 (0.10)\*    5.55 (0.33)†§           \<0.001    4.30 (0.05)     4.40 (0.07)      5.12 (0.24)\*\*††    0.003
  TG (mmol/L)‡          1.10 (0.04)    1.29 (0.09)      2.24 (0.26)†§           \<0.001    1.08 (0.04)     1.12 (0.06)      2.30 (0.20)\*\*††    \<0.001
  Ln CRP (mg/L)‡‡       0.09 (0.05)    0.45 (0.14)\*    −0.03 (0.39)            0.043      0.015 (0.061)   0.34 (0.084)¶    0.283 (0.302)        0.008
  Obesity, n (%)        152 (30.8)     32 (41.0)        5 (55.6)                0.134      108 (29.0)      72 (37.7)        9 (56.3)             0.024
  MS, n (%)             61 (12.4)      16 (20.8)        7 (77.8)†§              \<0.001    39 (10.5)       36 (18.8)¶       9 (60.0)\*\*††       \<0.001

\*\<5.7% vs 5.7%--6.4%.

†\< 5.7% vs \>6.4%.

‡Adjusted for age, sex and BMI.

§5.7%--6.4% vs \>6.4%.

¶\<5.5% vs 5.5%--6.1%.

\*\*\<5.5% vs \>6.1%.

††5.5%--6.1% vs \>6.1%.

‡‡Log transformed and adjust for age, sex and BMI; data were shown as mean (SE) or number (percentage).

2hBG, 2-hour blood glucose; 2hINS, 2-hour insulin; ADA, American Diabetes Association; BMI, body mass index; CRP, C-reacting protein; DBP, diastolic blood pressure; DI~O~, Oral Disposition Index; FBG, fasting blood glucose; FINS, fasting insulin; HDL-C: high-density lipoprotein cholesterol; HOMA-IR, the index of homeostasis model assessment of insulin resistance; IFG, impaired fasting glucose; IGI, Insulinogenic Index; IGT, impaired glucose tolerance; ISI, Insulin Sensitivity Index; LDL-C: low-density lipoprotein cholesterol; MS, metabolic syndrome; SBP, systolic blood pressure; T2DM: type 2 diabetes; TC, total cholesterol; TG, triglycerides; WC, waist circumference.

[Table 4](#T4){ref-type="table"} compares the ability of these differing HbA1c strata to delineate levels of β-cell dysfunction and insulin resistance derived from FPG and OGTT measures. Subjects in the HbA1c 5.5%--6.1% vs \<5.5% categories demonstrated no difference with regard to insulin resistance indices (HOMA-IR and ISI), and neither did those with HbA1c 5.7%--6.4% comparing with those \<5.7%. However, subjects with HbA1c 5.5%--6.1% showed a significantly lower IGI and DI~O~ compared with those with HbA1c \<5.5%. Notably, these differences were not as pronounced among groups classified using ADA criteria, especially with regard to IGI.

Regardless of the HbA1c thresholds employed, lipids measures (TC, TG and LDL-C) were significantly higher in diabetes than in normal or pre-diabetes categories, whereas hsCRP was highest in the pre-diabetic individuals (p\<0.05). Moreover, high HbA1c was associated with a higher prevalence of obesity, hypertension, IR and dyslipidaemia. Of those with HbA1c 5.5%--6.1%, 18.8% had MS, compared with only 10.5% of those with HbA1c \<5.5%. Applying our HbA1c thresholds ([table 5](#T5){ref-type="table"}), the ORs for dyslipidaemia, insulin resistance and MS in pre-diabetic versus non-diabetic individuals were 1.61, 2.19 and 2.09, respectively, which is somewhat higher than if ADA criteria were employed.

###### 

Age-adjusted and sex-adjusted ORs and 95% CIs for IR, MS and its components according to haemoglobin A1c categories

  --------------------------------------------------------------------------------------------------------------------------------------------
                  ADA criteria   P for trend      Our proposed criteria   P for trend                                                
  --------------- -------------- ---------------- ----------------------- ------------- --------- ---------------- ----------------- ---------
  Elevated BP     1 (ref)        1.55\            17.75\*\*\              0.002         1 (ref)   1.37\            5.63\*\*\         0.006
                                 (0.88 to 2.74)   (3.26 to 96.76)                                 (0.89 to 2.15)   (1.88 to 16.65)   

  Dyslipidaemia   1              1.53\            5.02\*\                 0.026         1         1.61\*\          3.34\*\           0.008
                                 (0.91 to 2.57)   (1.22 to 20.61)                                 (1.10 to 2.37)   (1.17 to 9.54)    

  IR              1              2.10\*\*\        21.50\*\*\              \<0.001       1         2.19\*\*\        8.69\*\           \<0.001
                                 (1.25to 3.55）   (2.56 to 180.56)                                (1.46 to 3.29)   (2.54 to 29.70)   

  MS              1              1.95\*\          20.80\*\*\              \<0.001       1         2.09\*\*\        11.63\*\*\        \<0.001
                                 (1.04 to 3.64)   (4.15 to 104.22)                                (1.27 to 3.45)   (3.85 to 35.10)   
  --------------------------------------------------------------------------------------------------------------------------------------------

\*Versus ref. p\<0.05; \*\*versus ref. p\<0.01.

ADA, American Diabetes Association; BP, blood pressure; IR, insulin resistance, defined by the index of homeostasis model assessment of insulin resistance \>2.6; MS, metabolic syndrome.

Discussion {#s4}
==========

This cross-sectional study demonstrates that the ADA's HbA1c thresholds of 5.7% and 6.5% had low sensitivity for classifying pre-diabetes (31.6%) and diabetes (63.6%) as defined by OGTT in a young Chinese population. Rather, we propose a threshold of 6.1% for identifying diabetes, with a sensitivity of 81.8% and specificity of 98.8%, and 5.5% for detecting pre-diabetes, with a sensitivity of 68.5% and specificity of 61.4%. We observed that the use of HbA1c thresholds of 5.5% and 6.1% would significantly improve the sensitivity of these measures without adversely affecting their specificities. Our data are in agreement with reports in children[@R22] which have concluded that HbA1c thresholds of 5.7%--6.4% and ≥6.5% are insufficient to detect pre-diabetes and diabetes.

Several studies have assessed HbA1c cut points for predicting diabetes or pre-diabetes against the gold-standard OGTT and concluded that HbA1c is a poor predictor of pre-diabetes and T2DM in young people. Lee *et al* [@R23] examined the ability of various tests to diagnose pre-diabetes and diabetes in obese children; comparing HbA1c, fructosamine and random glucose with OGTT. They found that all of these tests were poor discriminators, and led to missed cases of dysglycaemia in children. Similarly, Nowicka *et al* [@R24] suggested that an HbA1c of 5.8% for identifying T2DM in a multiethnic cohort of 1156 obese children and adolescents from the USA. Because of the lower prevalence of diabetes in paediatric as opposed to adult populations, the utility of A1c for detecting diabetes may be suspicious, and at the very least, thresholds require adjustment for the population under study. For this reason, Kester *et al* [@R25] suggested caution when adopting HbA1c as a principal diagnostic method in children, and called for prospective studies of pre-diabetes and T2DM in obese paediatric populations to determine HbA1c cut-off points.

FBG has been used as an inexpensive alternative to OGTT, especially when screening for MS. In our study, we compared HbA1c with FBG to detect dysglycaemia. In the subjects categorised as pre-diabetic by OGTT, 31.6% showed laboratory evidence of being at risk for DM on the basis of HbA1c, while only 5 (6.2%) were identified with IFG. Of the 10 classified with DM by OGTT, seven subjects were detected with HbA1c, while only four would be identified with DM on the basis of FBG. These findings are consistent with Chan *et al* who showed that FPG performed poorly in obese adolescents and young adults aged 10--18 years compared with HbA1c and OGTT when identifying dysglycaemia which was detected using a blinded continuous glucose monitoring device.[@R26] Furthermore, HbA1c may present certain advantages over other tests. For example, the multiethnic healthy study cohort demonstrated greater consistency of HbA1c versus FBG in a prospective trial in middle-school children.[@R27]

The debate over which test (HbA1c, FBG or 2hOGTT) is best to identify relevant glycaemic abnormalities in youth will ultimately require decades of prospective study to determine which test is most prognostic of cardiovascular and microvascular consequences. Until these long-term outcome studies become available, pre-diabetes and diabetes can be defined alternately by pathophysiological abnormalities associated with diabetes such as declining insulin sensitivity and β-cell function. Thus, the present study compares the ADA criteria with our proposed cut-off points to detect those alterations in insulin sensitivity and β-cell function based on OGTT. We demonstrate that an HbA1c in the range of 5.5%--6.1% is associated with reduced β-cell function (IGI, HOMA-β) as well as DI~O~ which is an established metabolic predictor of progression to diabetes.[@R28] We found progressively declining DI~O~ across the continuum of HbA1c from \<5.5% to 5.5%--6.1% to \> 6.1%. In contrast, the established ADA HbA1c criteria did not detect a difference in β-cell function (IGI) as HbA1c progressed from \<5.7% to 5.5%--6.4%. This implies that our proposed thresholds are more rational for defining diabetes risk, at least in a young Chinese population.

Studies in adults and children have shown that pre-diabetes is associated with increased prevalence of cardiovascular risk factors.[@R5] We also found a clustering of cardiovascular risk factors among subjects at risk for diabetes defined by our HbA1c thresholds. In the HbA1c 5.5%--6.1%, compared with those \<5.5%, elevated HbA1c was associated with known risk factors for CVD, including WC, DBP, TC, TG, LDL-C and hsCRP as well as a more than a twofold increased risk of having IR. Thus, our findings are consistent with an evolving consensus that HbA1c may identify a population with increased risk of microvascular and macrovascular complications.

CVD generally presents during adulthood, but the antecedents of this adult disease may be detectable in childhood. Elevated lipid and BP levels have been associated with an increased risk of CVD, and these risk factors track from childhood into adulthood.[@R30] Although this has not been definitively demonstrated in a prospective study of dysglycaemia which spans from childhood into adult life, it is reasonable to conclude that a similar persistence, if not a progression, of glycaemic abnormalities would be observed. Adolescents with pre-diabetes or T2DM face many years of hyperglycaemia and CVD, and thus, may have an increased life-time risk of developing complications. In fact, a large proportion of American adolescents have microalbuminuria and cardiovascular risk factors at diagnosis of T2DM.[@R32]

This study has several strengths and weaknesses. Considerable strength is drawn from the well-characterised cohort of adolescents and young adults at risk for diabetes. However, relatively few from this cohort had diabetes by ADA criteria. In addition, pubertal stage, which can influence insulin sensitivity and lipid levels, was not evaluated in this study. However, the small proportion of participants (\<12%) less than 16 years old suggests that the vast majority of participant were postpubertal, thus rendering this as only a minor concern. Furthermore, since puberty is associated with age, and we did include age as a covariate when comparing clinical features across HbA1c categories, there was some adjustment for the effect of pubertal stage. Finally, compared with our original population at baseline, the follow-up group is relatively small which may introduce the potential for bias. Nonetheless, there were no significant difference in gender, pubertal status or major cardiometabolic parameters at baseline between those who followed up versus those lost to follow-up.

In conclusion, the ADA's established HbA1c criteria for pre-diabetes and diabetes (5.7% and 6.5%) may not be appropriately applied to adolescents and young adults, especially in the Chinese population. Our findings suggest that those with HbA1c of 5.5%--6.1% already exhibit impaired β-cell function and increased cardiometabolic risk which may warrant intervention.
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